Published online before print February 27, 2006, doi: 10.1161/01.HYP.0000203732.03784.3b
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2006;47:634.)
© 2006 American Heart Association, Inc.
Editorial Commentaries |
Mineralocorticoid Receptors and Cardiovascular Damage
It’s Not Just Aldosterone
From Prince Henry’s Institute of Medical Research, Clayton, Victoria, Australia.
Correspondence to John Funder, Prince Henry’s Institute of Medical Research, P.O. Box 5152, Clayton, Victoria, Australia 3168. E-mail john.funder@princehenrys.org
An extract of the first 250 words of the full text is provided, because this article has no abstract. |
A decade before aldosterone was isolated and characterized, Hans Selye showed that administration of deoxycorticosterone acetate to rats sensitized by salt loading produced a vascular inflammatory response (polyarteritis) and tissue fibrosis. Fifty years later, Karl Weber and his colleagues showed that aldosterone and inappropriate salt intake produced cardiac hypertrophy and fibrosis1; this response is bilateral, independent of blood pressure,2 and preceded by progressive perivascular and interstitial inflammation.3 Clinically, patients with primary aldosteronism are more at risk than essential hypertensive patients with comparable blood pressure elevation, similarly suggesting a pathophysiological role for aldosterone in the cardiovascular system. On the basis of this evidence, experimental and clinical, there is thus no doubt that blocking aldosterone action in such circumstances is beneficial in terms of progression and outcomes.
It is, however, not as simple as that. In the present issue of Hypertension, Nagata et al4 show that mineralocorticoid receptor blockade attenuates cardiac hypertrophy and failure in low-renin, low-aldosterone hypertensive rats. The model is straightforward: salt sensitive Dahl rats are started at 7 weeks on an uncompromisingly high (8%) salt intake to which they not surprisingly respond by marked cardiac hypertrophy and clear signs of cardiac failure at age 19 weeks. Animals given eplerenone (30 or 100 mg/kg bw in the chow) to block mineralocorticoid receptors are progressively protected in terms of a number of cardiac/pulmonary indices. The authors conclude that in this model, mineralocorticoid receptor activation is not by the low levels of aldosterone, but by corticosterone, which circulates at total
Related Article:
Hypertension 2006 47: 656-664.
This article has been cited by other articles:
 |
|
 |
|
  A. Tasatargil, M. Tekcan, C. Celik-Ozenci, N. Ece Gungor, and B. Dalkiran Aldosterone-induced endothelial dysfunction of rat aorta: role of poly(ADP-ribose) activation Journal of Renin-Angiotensin-Aldosterone System, September 1, 2009; 10(3): 127 - 137. [Abstract] [PDF]
|
|
|
|
 |
|
 J. M. Luther, Z. Wang, J. Ma, N. Makhanova, H.-S. Kim, and N. J. Brown Endogenous Aldosterone Contributes to Acute Angiotensin II-Stimulated Plasminogen Activator Inhibitor-1 and Preproendothelin-1 Expression in Heart But Not Aorta Endocrinology, May 1, 2009; 150(5): 2229 - 2236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Lopez-Andres, C. Inigo, I. Gallego, J. Diez, and M. A. Fortuno Aldosterone Induces Cardiotrophin-1 Expression in HL-1 Adult Cardiomyocytes Endocrinology, October 1, 2008; 149(10): 4970 - 4978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Bauersachs and D. Fraccarollo More NO-No More ROS: Combined Selective Mineralocorticoid Receptor Blockade and Angiotensin-Converting Enzyme Inhibition for Vascular Protection Hypertension, March 1, 2008; 51(3): 624 - 625. [Full Text] [PDF]
|
|
|
|
|
|
E. P. Gomez-Sanchez, D. G. Romero, A. F. de Rodriguez, M. P. Warden, Z. Krozowski, and C. E. Gomez-Sanchez Hexose-6-Phosphate Dehydrogenase and 11{beta}-Hydroxysteroid Dehydrogenase-1 Tissue Distribution in the Rat Endocrinology, February 1, 2008; 149(2): 525 - 533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Oberleithner, C. Riethmuller, H. Schillers, G. A. MacGregor, H. E. de Wardener, and M. Hausberg Plasma sodium stiffens vascular endothelium and reduces nitric oxide release PNAS, October 9, 2007; 104(41): 16281 - 16286. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Cooper, A. Whaley-Connell, J. Habibi, Y. Wei, G. Lastra, C. Manrique, S. Stas, and J. R. Sowers Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2009 - H2023. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Stas, A. Whaley-Connell, J. Habibi, L. Appesh, M. R. Hayden, P. R. Karuparthi, M. Qazi, E. M. Morris, S. A. Cooper, C. D. Link, et al. Mineralocorticoid Receptor Blockade Attenuates Chronic Overexpression of the Renin-Angiotensin-Aldosterone System Stimulation of Reduced Nicotinamide Adenine Dinucleotide Phosphate Oxidase and Cardiac Remodeling Endocrinology, August 1, 2007; 148(8): 3773 - 3780. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Wintour Cortisol: a growth hormone for the fetal heart? Endocrinology, August 1, 2006; 147(8): 3641 - 3642. [Full Text] [PDF]
|
|
|
|
 |
|
 J.P. Habashi, D.P. Judge, T.M. Holm, R.D Cohn, B. Loeys, T.K. Cooper, L. Myers, E.C. Klein, G. Liu, C. Calvi, et al. Losartan in Marfan Syndrome--Beyond Blood Pressure Lowering: Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome. Science 312: 117-121, 2006 J. Am. Soc. Nephrol., July 1, 2006; 17(7): 1759 - 1764. [Full Text] [PDF]
|
|